A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE4

מצבים רפואיים

Chronic Lymphocytic Leukemia · Non-Hodgkin Lymphoma

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Cancer Specialists, LLC, Jacksonville, Florida, United States

    Contact: Principal Investigator (Ayed Ayed)
  • Sylvester Comprehensive Cancer Center, Miami, Florida, United States

    Study coordinator · 954-265-6549
    Contact: Principal Investigator (Alvaro Alencar)
  • Florida Cancer Specialists, Sarasota, Florida, United States

    Study coordinator · 941-377-9993
    Contact: Principal Investigator (Manish Patel)
  • The Emory Clinic, Atlanta, Georgia, United States

    Study coordinator · 404-778-3708
    Contact: Principal Investigator (Jonathon Cohen)
  • Northwestern University, Chicago, Illinois, United States

    Study coordinator · 60611-3013
    Contact: Principal Investigator (Shuo Ma)
  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Study coordinator · 617-632-5847
    Contact: Principal Investigator (Jennifer Brown)
  • Mayo Clinic- Minnesota, Rochester, Minnesota, United States

    Study coordinator · 507-284-2511
    Contact: Principal Investigator (Yucai Wang)
  • University Of Nebraska Medical Center, Omaha, Nebraska, United States

    Study coordinator · 402-559-5166
    Contact: Principal Investigator (Matthew Lunning)
  • Cayuga Cancer Center, Ithaca, New York, United States

    Study coordinator · 607-272-5414
    Contact: Principal Investigator (Cynthia Davis)
  • Northwell Health, Lake Success, New York, United States

    Study coordinator · 516-734-8959
    Contact: Principal Investigator (Steven Allen)
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States

    Study coordinator · 646-608-4273
    Contact: Principal Investigator (Prioty Islam)
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States

    Study coordinator · 646-608-4273
    Contact: Principal Investigator (Prioty Islam)
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States

    Contact: Principal Investigator (Prioty Islam)
  • Duke University Medical Center, Durham, North Carolina, United States

    Study coordinator · 919-684-8111
    Contact: Principal Investigator (Matthew McKinney)
  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Study coordinator · 614-293-3196
    Contact: Principal Investigator (Jennifer Woyach)
  • University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

    Study coordinator · 215-662-3933
    Contact: Principal Investigator (Sunita Nasta)
  • Tennessee Oncology, Nashville, Tennessee, United States

    Study coordinator · 615-524-4074
    Contact: Principal Investigator (Michael Byrne)
  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Study coordinator · 713-792-2860
    Contact: Principal Investigator (Michael Wang)
  • Swedish Cancer Institute, Seattle, Washington, United States

    Study coordinator · 98104-3588
    Contact: Principal Investigator (Swathi Namburi)
  • Medical College of Wisconsin, Milwaukee, Wisconsin, United States

    Study coordinator · 414-805-4600
    Contact: Principal Investigator (Nirav Shah)
  • Flinders Medical Centre, Adelaide, Australia

    Study coordinator · +61882044018
    Contact: Principal Investigator (Hui-Peng Lee)
  • Peter MacCallum Cancer Centre, Melbourne, Australia

    Study coordinator · 61396561158
    Contact: Principal Investigator (John Seymour)
  • Linear Clinical Research, Victoria, Australia

    Study coordinator · 61893467600
    Contact: Principal Investigator (Chan Cheah)
  • CHU de Nantes - Hotel Dieu, Nantes, France

    Study coordinator · +33240083271
    Contact: Principal Investigator (Thomas Gastinne)
  • IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi, Bologna, Italy

    Study coordinator · +39512144042
    Contact: Principal Investigator (Pier Luigi Zinzani)
  • Ospedale San Raffaele, Milan, Italy

    Study coordinator · +390226434797
    Contact: Principal Investigator (Paolo Ghia)
  • Nagoya Medical Center, Aichi-Ken, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Hirokazu Nagai)
  • National Cancer Center Hospital, Cho-ku, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Koji Izutsu)
  • National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Kaname Miyashita)
  • Tokai University Hospital- Isehara Campus, Isehara, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Yoshiaki Ogawa)
  • Tohoku University Hospital, Miyagi-Ken, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Noriko Fukuhara)
  • Hokkaido University Hospital, Sapporo, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Daigo Hashimoto)
  • Pratia MCM Krakow, Krakow, Poland

    Study coordinator · +48124003200
    Contact: Principal Investigator (Wojciech Jurczak)
  • Instytut Hermatologii I Transfuzjologii, Warsaw, Poland

    Study coordinator · +48223496334
    Contact: Principal Investigator (Ewa Lech-Maranda)
  • Seoul National University Hospital, Seoul, South Korea

    Study coordinator · 821071243234
    Contact: Principal Investigator (Ja Min Byun)
  • St James's University Hospital, Leeds, United Kingdom

    Study coordinator · +441132433144
    Contact: Principal Investigator (Talha Munir)
  • Churchill Hospital, Oxford, United Kingdom

    Study coordinator · +447728268414
    Contact: Principal Investigator (Toby Eyre)
  • Derriford Hospital, Plymouth, United Kingdom

    Study coordinator · +441752431043
    Contact: Principal Investigator (David John Lewis)
מובילי המחקר
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Study Director

    Eli Lilly and Company